查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1463913

外泌體治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按外泌體類型、來源、治療、應用、最終用戶、地區和競爭細分，2019-2029F

Exosome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Exosome Type, By Source, By Therapy, By Application, By End User, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年，全球外泌體治療市場估值為3,163 萬美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為41.34%。日益認知，全球外泌體治療市場正在經歷強勁成長。外泌體是細胞釋放的微小囊泡，因其在細胞之間轉移蛋白質、核酸和脂質等生物活性分子、影響各種生理和病理過程的能力而受到關注。

市場成長的主要驅動力是全球慢性疾病的盛行率不斷上升，例如癌症、心血管疾病、神經退化性疾病和發炎性疾病。外泌體提供了一種新方法，可以將治療貨物遞送至特定細胞，增強治療效果，同時減少副作用。重大貢獻。人們正在積極探索基於外泌體的癌症治療方法，包括藥物傳輸和免疫療法。

鑑於外泌體具有穿過血腦屏障的能力，神經退化性疾病為外泌體治療提供了另一個有前景的領域。這使它們成為治療阿茲海默症和帕金森氏症等疾病的潛在工具。此外，人們正在研究外泌體在再生醫學領域的組織修復和再生中的作用。的開發和商業化。在有希望的臨床前和早期臨床結果的推動下，研發活動的投資正在增加。

外泌體分離、純化和表徵方法的​​技術進步正在促進市場成長。產業參與者正在專注於開發基於外泌體的療法的可擴展且具有成本效益的製造流程。此外，了解外泌體生物學和貨物裝載技術正在提高治療干預的精度和功效。監管機構正在努力為基於外泌體的療法的開發和批准提供更明確的指南，強調產業與監管機構之間合作的重要性。

由於外泌體在疾病治療中的變革潛力，全球外泌體治療市場正見證顯著成長。持續的研究可能會進一步擴大市場，為患者提供新的前景，並將基於外泌體的療法確立為未來醫學的重要方面。

主要市場促進因素

慢性病盛行率增加

不斷崛起的研究與創新

主要市場挑戰

可擴展性和標準化

臨床試驗挑戰

缺乏理解和教育

主要市場趨勢

用於轉化奈米醫學的人工外泌體

不斷增加的夥伴關係和合作

外泌體治療市場的投資不斷成長

擴展診斷應用

細分市場洞察

外泌體類型見解

來源洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球外泌體治療市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 依外泌體類型（天然、混合）
    • 依來源分類（間質幹細胞、血液、體液、其他）
    • 依治療（免疫療法、化療、基因療法）
    • 依應用（代謝失調、腫瘤、心臟疾病、神經學、其他）
    • 按最終使用者（醫院、診所、學術研究機構、其他）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖
    • 按外泌體類型
    • 按來源
    • 透過治療
    • 按申請
    • 按最終用戶
    • 按地區

第 5 章：亞太地區外泌體治療市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按外泌體類型
    • 按來源
    • 透過治療
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲外泌體治療市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按外泌體類型
    • 按來源
    • 透過治療
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美外泌體治療市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按外泌體類型
    • 按來源
    • 透過治療
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲外泌體治療市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按外泌體類型
    • 按來源
    • 透過治療
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲外泌體治療市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按外泌體類型
    • 按來源
    • 透過治療
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球外泌體治療市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Aethlon Medical, Inc
  • AEGLE Therapeutics Corporation
  • Anjarium Biosciences AG
  • Exogenus Therapeutics SA
  • Lonza Group AG
  • Capricor Therapeutics, Inc
  • Avalon GloboCare Corp.
  • Stem Cell Medicine Ltd.
  • Evox Therapeutics Limited
  • EV Therapeutics

第 15 章：策略建議

第 16 章：關於我們免責聲明

簡介目錄
Product Code: 21063

Global Exosome Therapeutics Market was valued at USD 31.63 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 41.34% through 2029.Global Exosome Therapeutics Market is experiencing robust growth, fueled by the increasing recognition of exosomes' crucial role in intercellular communication and their potential therapeutic uses. Exosomes, tiny vesicles released by cells, are gaining attention for their ability to transfer bioactive molecules like proteins, nucleic acids, and lipids between cells, influencing various physiological and pathological processes.

A primary driver for market growth is the escalating prevalence of chronic diseases globally, such as cancer, cardiovascular diseases, neurodegenerative disorders, and inflammatory conditions. Exosomes offer a novel approach by delivering therapeutic cargo to specific cells, enhancing treatment effectiveness while reducing side effects.The oncology sector is expected to significantly contribute to the exosome therapeutics market due to exosomes' involvement in cancer progression and metastasis. There's active exploration of exosome-based therapies for cancer treatment, including drug delivery and immunotherapy.

Neurodegenerative diseases present another promising area for exosome therapeutics, given exosomes' ability to cross the blood-brain barrier. This positions them as potential vehicles for treating conditions like Alzheimer's and Parkinson's disease. Additionally, exosomes are being investigated for their role in tissue repair and regeneration in the field of regenerative medicine.The market is characterized by increasing collaborations between pharmaceutical companies, biotechnology firms, and research institutions to expedite the development and commercialization of exosome-based therapies. Investment in research and development activities is rising, driven by promising preclinical and early clinical results.

Technological advancements in exosome isolation, purification, and characterization methods are contributing to market growth. Industry players are focusing on developing scalable and cost-effective manufacturing processes for exosome-based therapeutics. Furthermore, understanding exosome biology and cargo loading techniques is improving the precision and efficacy of therapeutic interventions.The market faces challenges such as standardization of isolation and characterization methods, regulatory considerations, and complexities in large-scale production. Regulatory agencies are working on providing clearer guidelines for exosome-based therapy development and approval, highlighting the importance of collaborations between industry and regulatory bodies.

Global Exosome Therapeutics Market is witnessing significant growth driven by the transformative potential of exosomes in disease treatment. Continued research is likely to expand the market further, offering new prospects for patients and establishing exosome-based therapies as a crucial aspect of future medicine.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

Chronic diseases like cardiovascular diseases, diabetes, and cancer profoundly impact individuals' quality of life and life expectancy globally. Exosomes, small vesicles secreted by cells, are gaining considerable attention for their potential in treating these conditions. The rising prevalence of chronic diseases is propelling the global exosome therapeutics market to new heights.

Exosomes play a crucial role in influencing the immune system, making them valuable tools in autoimmune disease treatment and cancer immunotherapy. They can either suppress or stimulate immune responses, depending on the desired therapeutic outcome, thus driving the expansion of the global exosome therapeutics market.Exosome therapeutics utilize these tiny vesicles' potential to address various chronic diseases. Researchers have identified exosomes as promising carriers for delivering therapeutic cargo directly to affected cells, tissues, and organs. This approach offers several advantages over traditional drug delivery methods, including improved bioavailability, reduced toxicity, and the ability to target specific cells or tissues. The growing body of research in exosome therapeutics reveals their potential in addressing a wide range of chronic diseases, thereby fueling rapid growth in the exosome therapeutics market.

Cancer remains a significant challenge in the healthcare sector. According to the World Cancer Research Fund International, there were an estimated 18.1 million cancer cases globally in 2020, with 9.3 million in males and 8.8 million in females. Exosome therapeutics show considerable potential in both cancer diagnosis and treatment. Exosomes can carry valuable diagnostic markers for early cancer detection. Additionally, researchers are actively exploring exosomes as drug delivery vehicles for targeted cancer therapies. These nanocarriers can enhance the specificity and efficacy of cancer treatment while minimizing damage to healthy tissues, thereby contributing to the growth of the global exosome therapeutics market.

Rising Research and Innovation

The growth of the global exosome therapeutics market is significantly driven by the increasing focus on research and development. Scientists and medical professionals are continuously uncovering the potential applications of exosome-based therapies, leading to a surge in market growth.Pharmaceutical companies and academic institutions are making substantial investments in clinical studies and trials to assess the safety and efficacy of exosome-based therapies across various medical conditions, including neurodegenerative diseases, cancer, and cardiovascular disorders.

Advanced technologies for isolating, purifying, and characterizing exosomes have facilitated more precise and effective exosome-based therapies, contributing to market expansion.Researchers are also innovating new delivery methods to ensure exosomes reach their target tissues in sufficient quantities, such as through intravenous injection, driving further growth in the global exosome therapeutics market.

Moreover, exosomes are being explored as potential treatments for inflammatory diseases like Crohn's disease and ulcerative colitis, where they are used to deliver anti-inflammatory drugs and other therapeutic agents to sites of inflammation, bolstering overall market growth.Continued research into how exosomes interact with cells and distribute throughout the body is crucial for developing safe and effective therapies, thus further contributing to the expansion of the global exosome therapeutics market.

Key Market Challenges

Scalability and Standardization

Scaling up exosome production to meet the rising demand for therapeutics poses a significant challenge. While laboratories can generate exosomes in small quantities, achieving industrial-scale manufacturing is a different endeavor. The production process entails cell culture, exosome harvesting, and final product purification.

Developing standardized methods for characterizing exosomes and their cargo is of utmost importance. The lack of consistent protocols for exosome analysis hampers the assessment of their quality, potency, and safety. Furthermore, ensuring batch-to-batch consistency of exosome products is challenging due to their inherent heterogeneity.

Clinical Trial Challenges

Clinical trials play a crucial role in demonstrating the safety and efficacy of new drugs. However, designing and conducting clinical trials for exosome therapeutics present several challenges. One such challenge is the inherent complexity and heterogeneity of exosomes, making it difficult to standardize their production and establish reliable methods for measuring their activity.

When designing clinical trials for exosome therapeutics, careful consideration must be given to endpoints, patient populations, and treatment regimens. Selecting appropriate biomarkers and surrogate endpoints for diseases treated with exosomes can be particularly challenging. Additionally, determining the optimal dosing and treatment schedules is of utmost importance, although it can be a complex task.

Lack of Understanding and Education

Many scientists and healthcare professionals have limited knowledge of the intricacies of exosome biology and their potential therapeutic applications. This knowledge gap often results in skepticism and a hesitance to allocate time and resources to exosome research. Bridging this gap through comprehensive education and training programs is crucial for cultivating interest and understanding among scientists and clinicians.

Furthermore, patients and the general public lack awareness of exosome-based therapies and their potential benefits. Well-informed patients play a vital role in driving demand for these treatments and increasing participation in clinical trials. Implementing effective patient education campaigns is an essential step in closing this information gap.

Key Market Trends

Artificial Exosomes for Translational Nanomedicine

In recent times, artificial exosomes have been gaining prominence within the field of nanobiotechnology as a means to address the constraints associated with natural exosomes. Key categories of artificial exosomes encompass 'nanovesicles (NVs),' 'exosome-mimetic (EM),' and 'hybrid exosomes (HE),' which are generated through top-down, bottom-up, and biohybrid techniques, respectively. Artificial exosomes represent potent substitutes for natural exosomes in the realm of drug delivery. Artificial exosomes can be equipped with diagnostic markers, enabling them to serve as both drug delivery vehicles and diagnostic tools. This dual function enhances patient care by monitoring disease progression and treatment response in real-time.

Rising Partnerships and Collaborations

Numerous companies and research institutions are forging partnerships to combine their expertise in various facets of exosome research and development. The field of exosome research and therapeutic development demands substantial investments. Collaborations provide access to financial resources, empowering smaller companies and startups to compete with more established players. Public-private partnerships and academic-industry collaborations have played a pivotal role in securing funding for research and clinical trials. In August 2023, Evox Therapeutics officially disclosed their research findings, unveiling the discovery of novel exosome scaffold proteins that significantly enhance the efficient loading of drugs into exosomes, thereby serving a crucial purpose in therapeutics

Growing Investment in Exosome Therapeutics Market

Exosome therapeutics offer a wide range of potential applications, spanning from treating degenerative diseases to enhancing drug delivery and diagnostics. This versatility has garnered interest from investors seeking diverse investment opportunities. The growing understanding of exosome biology and their role in health and disease has instilled confidence in the therapeutic potential of exosomes. Encouraging preclinical and clinical studies have established a robust scientific foundation for investment. Stakeholders in the industry, including academic institutions, industry leaders, and startups, are forming strategic collaborations and partnerships to propel research and development in the exosome therapeutics field. These alliances not only facilitate capital flow but also foster knowledge exchange and technological advancements.

Expanding Diagnostic Applications

Exosomes contain a rich repository of data regarding the source cells, encompassing details about their genetic composition and protein constituents. This makes exosomes valuable diagnostic tools for various cancers. Beyond diagnostics, researchers are exploring exosomes as potential drug delivery vehicles for cancer therapies, improving precision and reducing side effects. The study of exosomes in neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, has unlocked new insights. Exosomes carry toxic proteins and other molecules implicated in these conditions, which open avenues for early diagnosis and therapeutic intervention

Segmental Insights

Exosome Type Insights

Basedon the Exosome Type, the global exosome therapeutics market can be classified into two types based on exosome type: Natural and Hybrid. Natural exosomes currently dominate the market due to their lower likelihood of triggering an immune response when used therapeutically. This is because they are derived from the patient's own cells or from a donor source. Moreover, natural exosomes play crucial roles in various biological processes and are currently under extensive research to uncover their potential applications. As a result, the market is expected to witness significant growth in the projected period.

Source Insights

According to the source, the global exosome therapeutics market can be categorized into mesenchymal stem cells, blood, body fluids, and others. Mesenchymal stem cells dominate the global exosome therapeutics market due to their demonstrated regenerative and anti-inflammatory properties in both preclinical and clinical studies. These exosomes derived from mesenchymal stem cells are currently under investigation for their potential in treating a wide range of conditions, including tissue injuries, neurological disorders, and inflammatory diseases.

Regional Insights

Based on Region, the global exosome therapeutics market can be segmented into North America, Asia Pacific, Europe, Middle East Africa and South America. North America dominates the global exosome therapeutics market due to the surge in clinical trials in the region involving exosome-based therapies, covering a wide range of medical conditions. This progress in clinical research has led to the commercialization of several exosome therapeutics, further establishing North America's dominance in the global market.

Key Market Players

Aethlon Medical, Inc.

AEGLE Therapeutics Corporation

Anjarium Biosciences AG

Exogenus Therapeutics SA

Lonza Group AG

Capricor Therapeutics Inc

Avalon GloboCare Corp.

Stem Cell Medicine Ltd.

Evox Therapeutics Limited.

EV Therapeutics

Report Scope:

In this report, the Global Exosome Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Exosome Therapeutics Market,By Exosome Type:

  • Natural
  • Hybrid

Exosome Therapeutics Market,By Source:

  • Mesenchymal Stem Cells
  • Blood
  • Body Fluids
  • Others

Exosome Therapeutics Market,By Therapy:

  • Immunotherapy
  • Chemotherapy
  • Gene Therapy

Exosome Therapeutics Market,By Application:

  • Metabolic Disorders
  • Oncology
  • Cardiac Disorders
  • Neurology
  • Others

Exosome Therapeutics Market,By End User:

  • Hospitals Clinics
  • Academic Research Institutions
  • Others

Exosome Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Exosome Therapeutics Market.

Available Customizations:

Global Exosome Therapeutics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Exosome Therapeutics Market Outlook

  • 4.1.Market Size Forecast
    • 4.1.1.By Value
  • 4.2.Market Share Forecast
    • 4.2.1.By Exosome Type (Natural, Hybrid)
    • 4.2.2.By Source (Mesenchymal Stem Cells, Blood, Body Fluids, Others)
    • 4.2.3.By Therapy (Immunotherapy, Chemotherapy, Gene Therapy)
    • 4.2.4.By Application (Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Others)
    • 4.2.5.By End User (Hospitals Clinics, Academic Research Institutions, Others)
    • 4.2.6.By Region
    • 4.2.7.By Company (2023)
  • 4.3.Market Map
    • 4.3.1.By Exosome Type
    • 4.3.2.By Source
    • 4.3.3.By Therapy
    • 4.3.4.By Application
    • 4.3.5.By End User
    • 4.3.6.By Region

5.Asia Pacific Exosome Therapeutics Market Outlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Exosome Type
    • 5.2.2.By Source
    • 5.2.3.By Therapy
    • 5.2.4.By Application
    • 5.2.5.By End User
    • 5.2.6.By Country
  • 5.3.Asia Pacific: Country Analysis
    • 5.3.1.China Exosome Therapeutics Market Outlook
      • 5.3.1.1.Market Size Forecast
        • 5.3.1.1.1.By Value
      • 5.3.1.2.Market Share Forecast
        • 5.3.1.2.1.By Exosome Type
        • 5.3.1.2.2.By Source
        • 5.3.1.2.3.By Therapy
        • 5.3.1.2.4.By Application
        • 5.3.1.2.5.By End User
    • 5.3.2.India Exosome Therapeutics Market Outlook
      • 5.3.2.1.Market Size Forecast
        • 5.3.2.1.1.By Value
      • 5.3.2.2.Market Share Forecast
        • 5.3.2.2.1.By Exosome Type
        • 5.3.2.2.2.By Source
        • 5.3.2.2.3.By Therapy
        • 5.3.2.2.4.By Application
        • 5.3.2.2.5.By End User
    • 5.3.3.Australia Exosome Therapeutics Market Outlook
      • 5.3.3.1.Market Size Forecast
        • 5.3.3.1.1.By Value
      • 5.3.3.2.Market Share Forecast
        • 5.3.3.2.1.By Exosome Type
        • 5.3.3.2.2.By Source
        • 5.3.3.2.3.By Therapy
        • 5.3.3.2.4.By Application
        • 5.3.3.2.5.By End User
    • 5.3.4.Japan Exosome Therapeutics Market Outlook
      • 5.3.4.1.Market Size Forecast
        • 5.3.4.1.1.By Value
      • 5.3.4.2.Market Share Forecast
        • 5.3.4.2.1.By Exosome Type
        • 5.3.4.2.2.By Source
        • 5.3.4.2.3.By Therapy
        • 5.3.4.2.4.By Application
        • 5.3.4.2.5.By End User
    • 5.3.5.South Korea Exosome Therapeutics Market Outlook
      • 5.3.5.1.Market Size Forecast
        • 5.3.5.1.1.By Value
      • 5.3.5.2.Market Share Forecast
        • 5.3.5.2.1.By Exosome Type
        • 5.3.5.2.2.By Source
        • 5.3.5.2.3.By Therapy
        • 5.3.5.2.4.By Application
        • 5.3.5.2.5.By End User

6.Europe Exosome Therapeutics Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Exosome Type
    • 6.2.2.By Source
    • 6.2.3.By Therapy
    • 6.2.4.By Application
    • 6.2.5.By End User
    • 6.2.6.By Country
  • 6.3.Europe: Country Analysis
    • 6.3.1.France Exosome Therapeutics Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Exosome Type
        • 6.3.1.2.2.By Source
        • 6.3.1.2.3.By Therapy
        • 6.3.1.2.4.By Application
        • 6.3.1.2.5.By End User
    • 6.3.2.Germany Exosome Therapeutics Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Exosome Type
        • 6.3.2.2.2.By Source
        • 6.3.2.2.3.By Therapy
        • 6.3.2.2.4.By Application
        • 6.3.2.2.5.By End User
    • 6.3.3.Spain Exosome Therapeutics Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Exosome Type
        • 6.3.3.2.2.By Source
        • 6.3.3.2.3.By Therapy
        • 6.3.3.2.4.By Application
        • 6.3.3.2.5.By End User
    • 6.3.4.Italy Exosome Therapeutics Market Outlook
      • 6.3.4.1.Market Size Forecast
        • 6.3.4.1.1.By Value
      • 6.3.4.2.Market Share Forecast
        • 6.3.4.2.1.By Exosome Type
        • 6.3.4.2.2.By Source
        • 6.3.4.2.3.By Therapy
        • 6.3.4.2.4.By Application
        • 6.3.4.2.5.By End User
    • 6.3.5.United Kingdom Exosome Therapeutics Market Outlook
      • 6.3.5.1.Market Size Forecast
        • 6.3.5.1.1.By Value
      • 6.3.5.2.Market Share Forecast
        • 6.3.5.2.1.By Exosome Type
        • 6.3.5.2.2.By Source
        • 6.3.5.2.3.By Therapy
        • 6.3.5.2.4.By Application
        • 6.3.5.2.5.By End User

7.North America Exosome Therapeutics Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Exosome Type
    • 7.2.2.By Source
    • 7.2.3.By Therapy
    • 7.2.4.By Application
    • 7.2.5.By End User
    • 7.2.6.By Country
  • 7.3.North America: Country Analysis
    • 7.3.1.United States Exosome Therapeutics Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Exosome Type
        • 7.3.1.2.2.By Source
        • 7.3.1.2.3.By Therapy
        • 7.3.1.2.4.By Application
        • 7.3.1.2.5.By End User
    • 7.3.2.Mexico Exosome Therapeutics Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Exosome Type
        • 7.3.2.2.2.By Source
        • 7.3.2.2.3.By Therapy
        • 7.3.2.2.4.By Application
        • 7.3.2.2.5.By End User
    • 7.3.3.Canada Exosome Therapeutics Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Exosome Type
        • 7.3.3.2.2.By Source
        • 7.3.3.2.3.By Therapy
        • 7.3.3.2.4.By Application
        • 7.3.3.2.5.By End User

8.South America Exosome Therapeutics Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Exosome Type
    • 8.2.2.By Source
    • 8.2.3.By Therapy
    • 8.2.4.By Application
    • 8.2.5.By End User
    • 8.2.6.By Country
  • 8.3.South America: Country Analysis
    • 8.3.1.Brazil Exosome Therapeutics Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Exosome Type
        • 8.3.1.2.2.By Source
        • 8.3.1.2.3.By Therapy
        • 8.3.1.2.4.By Application
        • 8.3.1.2.5.By End User
    • 8.3.2.Argentina Exosome Therapeutics Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Exosome Type
        • 8.3.2.2.2.By Source
        • 8.3.2.2.3.By Therapy
        • 8.3.2.2.4.By Application
        • 8.3.2.2.5.By End User
    • 8.3.3.Colombia Exosome Therapeutics Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Exosome Type
        • 8.3.3.2.2.By Source
        • 8.3.3.2.3.By Therapy
        • 8.3.3.2.4.By Application
        • 8.3.3.2.5.By End User

9.Middle East and Africa Exosome Therapeutics Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Exosome Type
    • 9.2.2.By Source
    • 9.2.3.By Therapy
    • 9.2.4.By Application
    • 9.2.5.By End User
    • 9.2.6.By Country
  • 9.3.MEA: Country Analysis
    • 9.3.1.South Africa Exosome Therapeutics Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Exosome Type
        • 9.3.1.2.2.By Source
        • 9.3.1.2.3.By Therapy
        • 9.3.1.2.4.By Application
        • 9.3.1.2.5.By End User
    • 9.3.2.Saudi Arabia Exosome Therapeutics Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Exosome Type
        • 9.3.2.2.2.By Source
        • 9.3.2.2.3.By Therapy
        • 9.3.2.2.4.By Application
        • 9.3.2.2.5.By End User
    • 9.3.3.UAE Exosome Therapeutics Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Exosome Type
        • 9.3.3.2.2.By Source
        • 9.3.3.2.3.By Therapy
        • 9.3.3.2.4.By Application
        • 9.3.3.2.5.By End User

10.Market Dynamics

  • 10.1.Drivers
  • 10.2.Challenges

11.Market Trends Developments

  • 11.1.Recent Developments
  • 11.2.Product Launches
  • 11.3.Mergers Acquisitions

12.Global Exosome Therapeutics Market: SWOT Analysis

13.Porter's Five Forces Analysis

  • 13.1.Competition in the Industry
  • 13.2.Potential of New Entrants
  • 13.3.Power of Suppliers
  • 13.4.Power of Customers
  • 13.5.Threat of Substitute Product

14.Competitive Landscape

  • 14.1.Aethlon Medical, Inc
    • 14.1.1.Business Overview
    • 14.1.2.Company Snapshot
    • 14.1.3.Product Services
    • 14.1.4.Financials (In case of listed)
    • 14.1.5.Recent Developments
    • 14.1.6.SWOT Analysis
  • 14.2.AEGLE Therapeutics Corporation
  • 14.3.Anjarium Biosciences AG
  • 14.4.Exogenus Therapeutics SA
  • 14.5.Lonza Group AG
  • 14.6.Capricor Therapeutics, Inc
  • 14.7.Avalon GloboCare Corp.
  • 14.8.Stem Cell Medicine Ltd.
  • 14.9.Evox Therapeutics Limited
  • 14.10.EV Therapeutics

15.Strategic Recommendations

16.About Us Disclaimer